Noviembre-Diciembre

Factor VIII delivery devices in haemophilia A Farm Hosp. 2016;40(6):579-603 - 595
Bibliografía
1. Aznar JA, Abad-Franch L, Cortina VR, Marco P. The national registry
of haemophilia A and B in Spain: results from a census of
patients. Haemophilia. 2009;15(6):1327-30.
2. Aznar JA, Lucía F, Abad-Franch L, Jiménez-Yuste V, Pérez R, Batlle J,
Balda I, et al. Haemophilia in Spain. Haemophilia. 2009;15(3):665-
75.
3. Treatment Guidelines Working Group of WFH. Guidelines for the
Management of Haemophilia [Monografía en Internet]. 2.ª ed.
Montreal: World Federation of Hemophilia; 2012 [Último acceso el
19 de enero de 2016]. Disponible en: www1.wfh.org/publications/
files/pdf-1472.pdf
4. Thornburg CD. Prophylactic factor infusions for patients with hemophilia:
challenges with treatment adherence. J Coagulation Disorders.
2010;2:9-14.
5. Remor E. Predictors of treatment difficulties and satisfaction with haemophilia
therapy in adult patients. Haemophilia. 2011;17(5):e901-5.
6. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance
with prophylaxis therapy in haemophilia. Haemophilia.
2001;7(4):392-6.
7. Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and
motivators of adherence to prophylactic treatment in haemophilia:
a systematic review. Haemophilia. 2013;19(3):355-61.
8. Petrini P. Identifying and overcoming barriers to prophylaxis in the
management of haemophilia. Haemophilia. 2007;13(Suppl 2):16-
22.
9. Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M.
Patient preference and ease of use for different coagulation factor
VIII reconstitution device scenarios: a cross-sectional survey in five
European countries. Patient Prefer Adherence. 2014;8:1713-20.
10. Teal S, Brohan E, Hettema Y, Humphrey L, Willgoss T, Hudgens S,
et al. Development and psychometric evaluation of a novel tool
for assessing patient perception and preference for haemophilia
treatment (HaemoPREF). Haemophilia. 2014;20(5):666-73.
11. Ajzen I. The theory of planned behavior. Organ Behav Hum Dec.
1991;50(2):179-211.
12. Vidovic N, Musso R, Klamroth R, Enríquez MM, Achilles K. Postmarketing
surveillance study of KOGENATE Bayer with Bio-Set
in patients with haemophilia A: evaluation of patients’ satisfaction
after switch to the new reconstitution system. Haemophilia.
2010;16(1):66-71.
13. Musso R, Santoro R, Coppola A, Marcucci M, Sottilotta G, Targhetta
R, et al. Patient preference for needleless factor VIII reconstitution
device: the Italian experience. Int J Gen Med. 2010;3:203-8.
14. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P,
et al. Factor VIII requirement to maintain a target plasma level in
the prophylactic treatment of severe hemophilia A: influences of
variance in pharmacokinetics and treatment regimens. J Thromb
Haemost. 2010;8(2):269-75.
15. Llewellyn CD, Miners AH, Lee CA, Harrington C, Weinman J. The
illness perceptions and treatment beliefs of individuals with severe
haemophilia and their role in adherence to home treatment. Psychology
& Health. 2003;18(2):185-200.